Pharmacology of Chlorpromazine

Introduction/Overview

Chlorpromazine, introduced into clinical practice in the 1950s, represents a landmark therapeutic agent in the history of psychopharmacology. Its discovery and subsequent application fundamentally altered the management of severe psychiatric disorders, facilitating the deinstitutionalization movement and establishing the foundation for modern neuroleptic therapy. As the prototypical typical, or first-generation, antipsychotic, chlorpromazine belongs to the phenothiazine class. Its primary clinical significance lies in the treatment of schizophrenia and other psychotic conditions, though its utility extends to several other therapeutic areas. The pharmacological profile of chlorpromazine is characterized by broad receptor antagonism, which underlies both its therapeutic efficacy and its considerable burden of adverse effects. Understanding this agent provides essential insights into the principles of antipsychotic drug action, the neurochemical basis of psychosis, and the historical evolution of psychiatric treatment.

Clinical Relevance and Importance

The clinical importance of chlorpromazine cannot be overstated. Prior to its introduction, treatment options for psychotic agitation and schizophrenia were severely limited, often involving physical restraint, insulin coma therapy, or psychosurgery. Chlorpromazine demonstrated that chemical intervention could effectively control the positive symptoms of psychosis, such as hallucinations, delusions, and thought disorder. This established the dopamine hypothesis of schizophrenia and validated the receptor-based approach to central nervous system drug development. While newer atypical antipsychotics with potentially improved tolerability profiles are now more commonly used as first-line agents, chlorpromazine remains a critical therapeutic option, particularly in treatment-resistant cases or in specific clinical scenarios such as intractable hiccups or severe nausea and vomiting. Its use continues to inform clinical practice, serving as a benchmark against which newer agents are compared.

Learning Objectives

• Describe the chemical classification of chlorpromazine and its relationship to pharmacological activity.
• Explain the complex mechanism of action, focusing on dopamine receptor antagonism and its implications for therapeutic and adverse effects.
• Outline the pharmacokinetic properties, including absorption, distribution, metabolism, and elimination pathways.
• Identify the approved therapeutic indications, common off-label uses, and the rationale for its application in each condition.
• Analyze the spectrum of adverse effects, from common anticholinergic effects to serious neurological and metabolic complications, and develop strategies for their management.
• Recognize significant drug-drug interactions and special population considerations to ensure safe prescribing.

Classification

Chlorpromazine is systematically classified within multiple hierarchical frameworks, each highlighting different aspects of its chemical and pharmacological nature.

Chemical Classification

Chemically, chlorpromazine is a tricyclic compound belonging to the phenothiazine family. Its structure consists of a central phenothiazine nucleus, which is a tricyclic system comprising two benzene rings fused to a thiazine ring. A chlorine atom is substituted at the 2-position of the phenothiazine ring system, contributing to its name and influencing its electron distribution and receptor affinity. A three-carbon propyl chain links the nitrogen of the phenothiazine ring to a terminal dimethylamino group. This aliphatic side chain configuration is a key determinant of its pharmacological profile, placing it within the subgroup of aliphatic phenothiazines, which are characterized by relatively lower potency but a high propensity for sedative and autonomic side effects compared to piperazine or piperidine subclasses.

Pharmacotherapeutic Classification

Therapeutically, chlorpromazine is classified as a first-generation antipsychotic (FGA) or a typical antipsychotic. This classification is primarily based on its historical introduction and its predominant mechanism of action as a potent antagonist at dopamine D₂ receptors. It is also accurately described as a neuroleptic, a term that encompasses its ability to produce a state of neurological quietude characterized by reduced initiative, psychomotor slowing, and emotional indifference, in addition to its antipsychotic effects. Beyond its psychiatric applications, it falls under the categories of antiemetic, due to its action in the chemoreceptor trigger zone, and adjunctive analgesic, for its potentiating effects on opioid analgesics.

Mechanism of Action

The therapeutic and adverse effects of chlorpromazine are mediated through its action as a broad-spectrum receptor antagonist within the central and peripheral nervous systems. Its pharmacological profile is not selective, leading to a wide array of biological actions.

Primary Pharmacodynamic Target: Dopamine Receptor Antagonism

The antipsychotic efficacy of chlorpromazine is primarily attributed to its competitive antagonism of postsynaptic dopamine D₂ receptors in the mesolimbic and mesocortical pathways of the brain. By blocking these receptors, chlorpromazine attenuates the excessive dopaminergic neurotransmission that is theorized to underlie the positive symptoms of psychosis, such as hallucinations and delusions. A receptor occupancy of approximately 60-80% at striatal D₂ receptors is typically associated with therapeutic response, while occupancy exceeding 80% significantly increases the risk of extrapyramidal side effects (EPS). Chlorpromazine also exhibits antagonistic activity at D₁, D₃, and D₄ dopamine receptor subtypes, though the clinical significance of this broader antagonism remains less clearly defined compared to its D₂ blockade.

Secondary Receptor Interactions

The non-selective nature of chlorpromazine results in significant interactions with several other neurotransmitter systems, which are largely responsible for its side effect profile.

• Adrenergic Receptor Antagonism: Chlorpromazine acts as an antagonist at both α₁– and α₂-adrenergic receptors. α₁-blockade contributes to orthostatic hypotension, dizziness, and reflex tachycardia. α₂-blockade may theoretically increase noradrenaline release, though this effect is often overshadowed by other actions.
• Muscarinic Cholinergic Receptor Antagonism: Antagonism at muscarinic (M₁) receptors produces anticholinergic effects, including dry mouth, blurred vision, constipation, urinary retention, and cognitive impairment. This antimuscarinic activity may also mitigate the risk of certain extrapyramidal symptoms.
• Histaminergic Receptor Antagonism: Potent blockade of histamine H₁ receptors is a major contributor to the sedative and hypnotic properties of chlorpromazine, as well as to weight gain.
• Serotonergic Receptor Antagonism: Chlorpromazine demonstrates antagonism at several serotonin receptor subtypes, particularly 5-HT_2A and 5-HT_2C. This activity may contribute to both therapeutic effects, such as potential mitigation of negative symptoms, and adverse effects like weight gain.

Cellular and Molecular Mechanisms

At the cellular level, dopamine D₂ receptor antagonism by chlorpromazine inhibits adenylate cyclase activity via G_i/o protein coupling, leading to reduced intracellular cyclic adenosine monophosphate (cAMP) production. It also modulates potassium and calcium channel conductance. Prolonged administration leads to adaptive changes in neuronal signaling, including depolarization block of dopaminergic neurons in the midbrain and upregulation of dopamine receptors, which may be linked to both therapeutic effects and complications like tardive dyskinesia. The drug’s action in the chemoreceptor trigger zone (CTZ) of the area postrema, where the blood-brain barrier is more permeable, underlies its potent antiemetic effect.

Pharmacokinetics

The pharmacokinetic profile of chlorpromazine is complex, characterized by significant interindividual variability, extensive metabolism, and a high volume of distribution.

Absorption

Chlorpromazine is readily absorbed from the gastrointestinal tract following oral administration. However, it undergoes extensive first-pass metabolism in the intestinal wall and liver, resulting in an oral bioavailability that is highly variable, typically ranging from 20% to 50%. Absorption can be erratic and is influenced by factors such as gastric pH, intestinal motility, and the presence of food. Intramuscular administration provides a more rapid and predictable onset of action, with bioavailability approaching 100%, making this route preferable for the management of acute agitation. Peak plasma concentrations (C_max) after oral dosing are generally observed within 2 to 4 hours.

Distribution

Chlorpromazine is widely distributed throughout body tissues due to its high lipophilicity. It readily crosses the blood-brain barrier and the placental barrier, and is distributed into breast milk. The volume of distribution is large, often exceeding 10 L/kg, indicating extensive tissue binding. In plasma, chlorpromazine is highly bound (≥95%) to proteins, primarily albumin and α₁-acid glycoprotein. This high protein binding can have implications for drug interactions with other highly protein-bound agents, though the clinical significance of such displacement interactions is often limited.

Metabolism

Metabolism of chlorpromazine is extensive and occurs primarily in the liver via the cytochrome P450 system. The major isoenzymes involved are CYP2D6 and CYP1A2, with contributions from CYP3A4 and CYP2C19. Metabolism proceeds through multiple pathways, including aromatic hydroxylation, N-demethylation, sulfoxidation, and glucuronide conjugation. Over 100 metabolites have been identified, many of which are pharmacologically active. Notably, 7-hydroxychlorpromazine is a major active metabolite with significant antipsychotic activity. The extensive and polymorphic nature of its metabolism, particularly via CYP2D6, accounts for much of the observed interpatient variability in plasma concentrations, clinical response, and toxicity.

Excretion

Elimination of chlorpromazine and its metabolites occurs predominantly via renal excretion. Less than 5% of an administered dose is excreted unchanged in the urine. The majority is eliminated as conjugated metabolites (glucuronides and sulfates) through both renal and biliary pathways. The elimination half-life (t_1/2) of chlorpromazine is highly variable, ranging from approximately 16 to 30 hours in most individuals, but can be prolonged in poor metabolizers or in the presence of hepatic impairment. The pharmacokinetics are generally non-linear at higher doses due to saturation of metabolic pathways.

Dosing Considerations

Dosing must be highly individualized, starting low and titrating slowly to achieve therapeutic effect while minimizing adverse reactions. For psychosis in adults, oral dosing often begins at 25-50 mg two to three times daily, with gradual increases to a typical therapeutic range of 300-1000 mg per day, though some patients may require doses outside this range. Intramuscular doses for acute agitation are typically 25-50 mg, which may be repeated every 1-4 hours as needed. Steady-state plasma concentrations are usually achieved after 4 to 7 days of consistent dosing. Therapeutic drug monitoring is not routinely performed but may be considered in cases of treatment failure, suspected toxicity, or to assess adherence.

Therapeutic Uses/Clinical Applications

Chlorpromazine possesses a range of clinical applications stemming from its diverse receptor profile. Its use requires careful consideration of the risk-benefit ratio due to its significant adverse effect potential.

Approved Indications

• Schizophrenia and Other Psychotic Disorders: This remains the primary indication. It is effective in managing positive symptoms (agitation, hallucinations, delusions). Its utility for negative symptoms (apathy, social withdrawal) is generally considered limited, and it may even exacerbate them.
• Bipolar Disorder, Manic Phase: Chlorpromazine is used to control acute manic episodes, particularly when marked by severe agitation, aggression, or psychosis. It is often employed when mood stabilizers or atypical antipsychotics are not effective or tolerated.
• Severe Nausea and Vomiting: Its potent antiemetic action makes it useful for controlling severe, intractable nausea and vomiting, such as that associated with chemotherapy, radiation therapy, or postoperative states. Its use has been largely superseded by more selective antiemetics with fewer side effects.
• Intractable Hiccups: Chlorpromazine is often effective for the management of persistent, debilitating hiccups (singultus) that are unresponsive to other measures, likely due to its central depressant effects on the hiccup reflex arc.
• Acute Intermittent Porphyria: It may be used as an adjunct to manage the neuropsychiatric symptoms (agitation, anxiety, psychosis) associated with acute attacks, though its use requires extreme caution due to the potential to exacerbate the condition.
• Preoperative Sedation: It is sometimes used for its calming and antiemetic effects prior to surgery.

Off-Label Uses

Several off-label applications exist, supported by varying degrees of clinical evidence. These include adjunctive treatment for severe behavioral disturbances in dementia (though with a significant black box warning for increased mortality in this population), management of delirium in hospitalized patients, treatment of certain anxiety disorders when other agents have failed, and as an adjunct for pain management, particularly in terminal care, due to its potentiating effects on opioids and its own mild analgesic properties. Its use in Tourette syndrome and Huntington’s disease for tic suppression has also been reported, though it is not a first-line agent for these conditions.

Adverse Effects

The adverse effect profile of chlorpromazine is extensive, reflecting its broad receptor antagonism. Effects range from common and bothersome to rare and life-threatening.

Common Side Effects

• Central Nervous System: Sedation, drowsiness, and impaired cognitive function are frequent, especially during initial treatment. Dizziness and headache may also occur.
• Autonomic Nervous System: Anticholinergic effects are prominent and include dry mouth (xerostomia), blurred vision due to cycloplegia, constipation, urinary hesitancy or retention, and reduced sweating. Adrenergic blockade leads to orthostatic hypotension, palpitations, and reflex tachycardia.
• Endocrine/Metabolic: Hyperprolactinemia is a direct consequence of D₂ blockade in the tuberoinfundibular pathway, potentially causing galactorrhea, gynecomastia, menstrual irregularities, sexual dysfunction, and reduced bone mineral density with long-term use. Weight gain is common.
• Dermatological: Photosensitivity reactions can occur, necessitating sun protection. Skin rashes, including contact dermatitis in healthcare workers, are possible.

Serious and Rare Adverse Reactions

• Extrapyramidal Symptoms (EPS): These are dose-related neurological effects resulting from D₂ blockade in the nigrostriatal pathway.
  • Acute Dystonia: Sudden, sustained muscle contractions, often involving the neck (torticollis), eyes (oculogyric crisis), or jaw. Typically occurs early in treatment.
  • Parkinsonism: Bradykinesia, rigidity, tremor, and masked facies, resembling idiopathic Parkinson’s disease.
  • Akathisia: A subjective feeling of inner restlessness and an objective inability to remain still, which is often distressing and can be mistaken for agitation.
• Tardive Dyskinesia (TD): A potentially irreversible syndrome of involuntary, choreoathetoid movements, most commonly affecting the orofacial region (lip smacking, tongue protrusion). Risk increases with duration of treatment and cumulative dose. The incidence is estimated at 3-5% per year of treatment.
• Neuroleptic Malignant Syndrome (NMS): A rare but life-threatening medical emergency characterized by hyperthermia, severe muscle rigidity, altered mental status, autonomic instability (labile blood pressure, tachycardia), and elevated creatine kinase. Mortality can be significant if not recognized and treated promptly.
• Cardiovascular Effects: QT interval prolongation on the electrocardiogram, which may predispose to torsades de pointes, a polymorphic ventricular tachycardia. This risk is heightened with high doses, concomitant use of other QT-prolonging drugs, and electrolyte disturbances.
• Hematological Effects: Agranulocytosis, though rare, is a serious idiosyncratic reaction characterized by a profound drop in neutrophil count, leading to high risk of infection. It typically occurs within the first 2-3 months of therapy.
• Hepatotoxicity: Cholestatic jaundice may occur, usually within the first month of treatment, and is generally reversible upon discontinuation.
• Ocular Effects: Lenticular and corneal deposits may occur with long-term, high-dose therapy, potentially affecting vision. Regular ophthalmological examinations are recommended for patients on prolonged treatment.

Black Box Warnings

Chlorpromazine carries a black box warning, the strongest safety alert mandated by regulatory agencies. This warning highlights an increased risk of mortality in elderly patients with dementia-related psychosis. Epidemiological studies have shown that treatment with conventional antipsychotics, including chlorpromazine, is associated with a 1.6 to 1.7-fold increase in the risk of death, primarily from cardiovascular events or infections such as pneumonia. Consequently, chlorpromazine is not approved for the treatment of dementia-related behavioral disturbances.

Drug Interactions

The pharmacodynamic and pharmacokinetic properties of chlorpromazine create a substantial potential for clinically significant drug interactions.

Major Pharmacodynamic Interactions

• CNS Depressants: Additive or synergistic depression of the central nervous system can occur with concomitant use of alcohol, benzodiazepines, barbiturates, opioids, sedating antihistamines, and other antipsychotics. This combination significantly increases the risk of profound sedation, respiratory depression, and impaired psychomotor performance.
• Antihypertensive Agents: The α₁-adrenergic blocking activity of chlorpromazine can potentiate the effects of other antihypertensive drugs, leading to severe orthostatic hypotension and syncope. This interaction is particularly notable with vasodilators and other α-blockers.
• Anticholinergic Agents: Concurrent use with other drugs possessing antimuscarinic activity (e.g., tricyclic antidepressants, antiparkinsonian agents like benztropine, some antihistamines) can lead to an anticholinergic toxidrome, characterized by hyperthermia, delirium, ileus, urinary retention, and tachycardia.
• QT-Prolonging Drugs: Co-administration with other agents known to prolong the QT interval (e.g., class IA and III antiarrhythmics, certain antibiotics like macrolides and fluoroquinolones, some antidepressants) may have an additive effect on cardiac repolarization, substantially increasing the risk of torsades de pointes.
• Dopamine Agonists: Chlorpromazine antagonizes the effects of direct and indirect dopamine agonists, such as levodopa, bromocriptine, and pramipexole, potentially worsening symptoms of Parkinson’s disease or restless legs syndrome.

Major Pharmacokinetic Interactions

• CYP2D6 Inhibitors: Drugs like fluoxetine, paroxetine, bupropion, and quinidine can inhibit the metabolism of chlorpromazine, leading to elevated plasma concentrations and an increased risk of toxicity, including EPS and sedation.
• CYP1A2 Inhibitors: Inhibitors such as fluvoxamine and ciprofloxacin can similarly increase chlorpromazine levels.
• CYP Inducers: Agents that induce hepatic cytochrome P450 enzymes, particularly CYP1A2 and CYP3A4 (e.g., carbamazepine, phenobarbital, phenytoin, rifampin, tobacco smoke), can accelerate the metabolism of chlorpromazine, potentially leading to subtherapeutic plasma concentrations and treatment failure.
• Antacids and Adsorbents: Concurrent administration may reduce the gastrointestinal absorption of chlorpromazine. Dosing should be separated by at least 2 hours.

Contraindications

Absolute contraindications to the use of chlorpromazine include known hypersensitivity to phenothiazines, severe central nervous system depression or comatose states, significant bone marrow suppression, and concomitant use with large doses of other CNS depressants. It is also contraindicated in patients with a history of neuroleptic malignant syndrome. Relative contraindications, requiring extreme caution and careful risk-benefit assessment, include severe cardiovascular disease, Parkinson’s disease, seizure disorders, glaucoma (particularly angle-closure), prostatic hypertrophy, severe hepatic or renal impairment, and a history of tardive dyskinesia.

Special Considerations

The use of chlorpromazine requires tailored approaches in specific patient populations due to altered pharmacokinetics, pharmacodynamics, or unique risk profiles.

Pregnancy and Lactation

Chlorpromazine is classified as Pregnancy Category C by the traditional FDA classification system, indicating that animal reproduction studies have shown adverse effects, and there are no adequate and well-controlled studies in pregnant women. It may be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Neonates exposed to antipsychotics during the third trimester are at risk for extrapyramidal signs or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding difficulty) after delivery. Chlorpromazine is excreted in human breast milk in low concentrations. Due to the potential for serious adverse reactions in nursing infants, including sedation and developmental effects, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Considerations

The safety and effectiveness of chlorpromazine in children under 6 years of age have not been established. In older children and adolescents, it may be used for severe behavioral disorders or psychosis, but dosing must be conservative and carefully monitored. Children and adolescents may be more susceptible to certain adverse effects, particularly dystonic reactions and sedation. They may also be more sensitive to the effects of hyperprolactinemia on growth and sexual development. Long-term effects on the developing brain are not fully understood.

Geriatric Considerations

Elderly patients often exhibit increased sensitivity to the effects of chlorpromazine. Age-related reductions in hepatic metabolism, renal excretion, and lean body mass, along with increased receptor sensitivity, can lead to higher plasma concentrations and an exaggerated response to both therapeutic and adverse effects. The risk of orthostatic hypotension, sedation, anticholinergic effects (including confusion and delirium), EPS, and falls is significantly increased. As noted in the black box warning, elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death. Therefore, the lowest effective dose should be used, with very slow titration and close monitoring.

Renal and Hepatic Impairment

In patients with renal impairment, dose adjustment is not routinely required as less than 5% of the drug is excreted unchanged. However, caution is advised due to the potential accumulation of active metabolites, though their renal handling is not well characterized. In patients with hepatic impairment, chlorpromazine should be used with extreme caution and at reduced doses. The drug is extensively metabolized by the liver, and impaired hepatic function can lead to significantly elevated plasma levels and prolonged half-life, increasing the risk of toxicity, including sedation, hypotension, and hepatotoxicity itself. Baseline and periodic liver function tests are recommended during long-term therapy.

Summary/Key Points

• Chlorpromazine is the prototypical first-generation (typical) antipsychotic of the aliphatic phenothiazine class, with historical and ongoing clinical significance in managing psychosis.
• Its primary mechanism of action is antagonism of dopamine D₂ receptors in the mesolimbic pathway, but its broad-spectrum antagonism of adrenergic, muscarinic, histaminergic, and serotonergic receptors underlies a wide array of both therapeutic and adverse effects.
• Pharmacokinetics are characterized by variable oral bioavailability due to extensive first-pass metabolism, high lipophilicity and volume of distribution, complex hepatic metabolism primarily via CYP2D6 and CYP1A2, and renal excretion of metabolites.
• Major therapeutic indications include schizophrenia, acute mania, severe nausea/vomiting, and intractable hiccups.
• The adverse effect profile is substantial, including common anticholinergic and sedative effects, serious neurological effects (EPS, tardive dyskinesia, NMS), metabolic effects (hyperprolactinemia, weight gain), cardiovascular effects (QT prolongation, hypotension), and rare but serious hematological and hepatic reactions.
• It carries a black box warning for increased mortality in elderly patients with dementia-related psychosis.
• Numerous drug interactions exist, both pharmacodynamic (additive CNS depression, hypotension, anticholinergic effects) and pharmacokinetic (via CYP450 inhibition or induction).
• Special caution is required in pediatric, geriatric, pregnant, and hepatically impaired populations, with a mandate for dose individualization and vigilant monitoring.

Clinical Pearls

• When initiating therapy, “start low and go slow” to minimize initial sedation and orthostatic hypotension, allowing for tolerance to develop to some of these acute side effects.
• Patients should be counseled to rise slowly from sitting or lying positions to prevent orthostatic syncope and to use sun protection due to photosensitivity.
• The development of akathisia must be carefully distinguished from worsening agitation or psychosis, as increasing the antipsychotic dose will exacerbate akathisia.
• Regular monitoring for signs of tardive dyskinesia (using a standardized exam like the AIMS) is essential for patients on long-term therapy to detect the condition at its earliest, potentially more reversible, stage.
• Given its significant side effect burden and the availability of alternative agents, the use of chlorpromazine should be reserved for situations where its specific profile is advantageous or when other treatments have failed.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.